Literature DB >> 9398695

Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women.

H Campos1, B W Walsh, H Judge, F M Sacks.   

Abstract

Estrogen decreases low density lipoprotein (LDL) particle size, and smaller LDL particles are associated with coronary atherosclerosis. To understand the metabolic basis for this change, we studied the effect of oral 17 beta-estradiol (2 mg/day) on apolipoprotein B-100 (apoB) metabolism, in eight healthy postmenopausal women. The study was a randomized, double blinded, placebo-controlled, cross-over trial with intervention sequences of 6 weeks each. ApoB in very low density lipoprotein, intermediate density lipoprotein, and LDL subclasses was endogenously labeled with [D3]L-leucine, and metabolic rates were calculated by computer modeling. The overall effect of oral estrogen therapy on apoB metabolism was to accelerate the fractional catabolic rates of all particles studied and production rates of all except IDL. For light LDL (density = 1.019-1.036 g/mL), estrogen increased the mean fractional catabolic rate by 63% from 0.59 to 0.96 pools/day (P = 0.02), whereas the production rate increased by a lesser amount (42%) from 575 to 817 mg/day (P = 0.10). These metabolic changes reduced light LDL cholesterol and apoB concentrations by 26% (P = 0.005) and 19% (P = 0.03), respectively. In contrast, dense LDL (density = 1.036-1.063 g/mL) cholesterol and apoB concentrations were unchanged by the intervention, as both the apoB fractional catabolic rate and production rate were significantly increased by similar amounts, 39% (from 0.41 to 0.57 pools/day, P = 0.01) and 38% (from 434 to 601 mg/day; P = 0.003), respectively. Estrogen decreased the predominant LDL peak particle size from 273 to 268 A (P = 0.04). Thus, estrogen therapy increases the clearance of both light and dense LDL, counteracting increases in production rates. The reduced plasma residence times of light and dense LDL both may be antiatherogenic, even though, for dense LDL, the concentration did not change.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398695     DOI: 10.1210/jcem.82.12.4437

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Richard W Browne; Audrey J Gaskins; Maurizio Trevisan; Anne Z Steiner; Julie L Daniels; Cuilin Zhang; Neil J Perkins; Jean Wactawski-Wende
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

Review 2.  Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.

Authors:  Enrique F Schisterman; Sunni L Mumford; Lindsey A Sjaarda
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

3.  Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice.

Authors:  Brian T Palmisano; Thao D Le; Lin Zhu; Yoon Kwang Lee; John M Stafford
Journal:  J Lipid Res       Date:  2016-06-27       Impact factor: 5.922

4.  Estrogen deficiency after menopause does not result in male very-low-density lipoprotein metabolism phenotype.

Authors:  Faidon Magkos; Elisa Fabbrini; B Selma Mohammed; Bruce W Patterson; Samuel Klein; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

5.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

6.  Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Michael C d'Emden; Alicia J Jenkins; Liping Li; Diana Zannino; Kristy P Mann; James D Best; Bronwyn G A Stuckey; Kris Park; Juha Saltevo; Anthony C Keech
Journal:  Diabetologia       Date:  2014-08-23       Impact factor: 10.122

7.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

8.  Effect of Menstrual Cycle Phases on Plasma Lipid and Lipoprotein Levels in Regularly Menstruating Women.

Authors:  Shilpi Vashishta; Sushila Gahlot; Rajni Goyal
Journal:  J Clin Diagn Res       Date:  2017-05-01

9.  Cardiovascular risk factors and menstrual cycle phase in pre-menopausal women.

Authors:  A R Saxena; E W Seely; A B Goldfine
Journal:  J Endocrinol Invest       Date:  2011-10-03       Impact factor: 4.256

10.  Effects of gender and gonadectomy on growth and plasma cholesterol levels in pigs.

Authors:  Chong-Eon Lee; Nam-Young Kim; Kyu-Il Kim
Journal:  Nutr Res Pract       Date:  2009-03-31       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.